Literature DB >> 20371257

Neuregulin 1-induced AKT phosphorylation in monozygotic twins discordant for schizophrenia.

Imola Seres1, Oguz Kelemen, György Benedek, Szabolcs Kéri.   

Abstract

Patients with schizophrenia exhibit decreased neuregulin 1 (NRG1)-stimulated AKT phosphorylation in peripheral lymphoblasts. Here, we examined this peripheral marker in monozygotic twins discordant for schizophrenia and in healthy monozygotic twins without psychiatric disorders. B lymphoblasts were stimulated with NRG1a (65 amino-acid residue recombinant protein from the epidermal growth factor [EGF] domain) for 30min. The protein isolated from the cells was analysed by Western blotting. The dependent measure was the ratio of phosphorylated AKT (pAKT) and total AKT at baseline (without NRG1 stimulation) and after NRG1 stimulation (pAKT/AKT). The results revealed that in the case of the unaffected co-twins of patients with schizophrenia, NRG1-stimulated pAKT/AKT ratio was in between the values of their co-twins with schizophrenia and that of the healthy control twin pairs. When the affected twins with schizophrenia were compared with their unaffected co-twins using a Mann-Whitney U-test, we found significantly lower NRG1-induced pAKT/AKT ratios in the patients relative to their unaffected co-twins (p=0.004). However, using a more conservative analysis (Kruskal-Wallis ANOVA followed tests for multiple comparisons), this difference was not significant. The unaffected co-twins of patients with schizophrenia did not differ significantly from the healthy control twins. In the baseline condition, the pAKT/AKT ratios were similar in all groups. These results indicate that impaired AKT-related intracellular signaling is partly related to the developed illness and cannot fully be explained by the genetic background of schizophrenia. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20371257     DOI: 10.1016/j.neuint.2010.03.018

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  6 in total

1.  Neuregulin 1-induced AKT and ERK phosphorylation in patients with fragile X syndrome (FXS) and intellectual disability associated with obstetric complications.

Authors:  Tamás Kovács; Boglárka Bánsági; Oguz Kelemen; Szabolcs Kéri
Journal:  J Mol Neurosci       Date:  2014-02-23       Impact factor: 3.444

2.  GSK3β and mTORC1 Represent 2 Distinct Signaling Markers in Peripheral Blood Mononuclear Cells of Drug-Naive, First Episode of Psychosis Patients.

Authors:  Petros Petrikis; Alexandra Polyzou; Kyriaki Premeti; Argyro Roumelioti; Andreas Karampas; Georgios Georgiou; Dionysios Grigoriadis; George Leondaritis
Journal:  Schizophr Bull       Date:  2022-09-01       Impact factor: 7.348

3.  Neurodevelopmental concepts of schizophrenia in the genome-wide association era: AKT/mTOR signaling as a pathological mediator of genetic and environmental programming during development.

Authors:  Kristy R Howell; Amanda J Law
Journal:  Schizophr Res       Date:  2019-09-12       Impact factor: 4.939

4.  Investigation of gene effects and epistatic interactions between Akt1 and neuregulin 1 in the regulation of behavioral phenotypes and social functions in genetic mouse models of schizophrenia.

Authors:  Ching-Hsun Huang; Ju-Chun Pei; Da-Zhong Luo; Ching Chen; Yi-Wen Chen; Wen-Sung Lai
Journal:  Front Behav Neurosci       Date:  2015-01-29       Impact factor: 3.558

5.  PKBγ/AKT3 loss-of-function causes learning and memory deficits and deregulation of AKT/mTORC2 signaling: Relevance for schizophrenia.

Authors:  Kristy R Howell; Kirsten Floyd; Amanda J Law
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

6.  Disparate Effects of Lithium and a GSK-3 Inhibitor on Neuronal Oscillatory Activity in Prefrontal Cortex and Hippocampus.

Authors:  Tuan Nguyen; Theresa Fan; Susan R George; Melissa L Perreault
Journal:  Front Aging Neurosci       Date:  2018-01-12       Impact factor: 5.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.